Market Access and Value Communication
Development of a clear, compelling value story that resonates with payers, healthcare leaders, and other stakeholders is a key step in supporting informed healthcare decision-making and improving patient access to healthcare interventions.
A value communication narrative that resonates with your audience
We partner with pharmaceutical and biotech organisations to develop evidence-led market access and value communication strategies that optimise access from global planning through to local submission, support confident decision-making, and strengthen reimbursement narratives.
How we help
→ A value story payers can act on
Evidence-based value stories translating complex evidence into clear, relevant insights that support payer evaluation and access decisions.
→ Ensuring consistency between stakeholders
Value message hierarchies, value story slide decks, infographics, objection handlers, and briefing books, built to enable internal teams and all stakeholders to all work from one consistent, evidence-based narrative.
→ Bespoke materials to suit your needs
Global/core value and reimbursement dossiers, and local-country adaptations, so your evidence is shaped to the exact requirements of the audience reviewing it, not a generic template stretched to fit.
→ Evidence published as a citable output
Publication of your evidence to extend its reach and credibility beyond a single submission.
Support across the full pathway
We support clients from global deliverable development, through local payer submission, and into market launch, helping you maintain ownership, continuity, and efficiency across the full market access pathway.
✔ Global-to-local continuity
One team can carry the value story from core materials into country-specific adaptations.
✔ Greater efficiency
Avoid restarting with a new team at each stage, reducing duplication and preserving strategic context.
✔ Clear ownership
Benefit from joined-up support that keeps evidence, messaging, and submission requirements aligned.
Why work with us?
Our market access and value communication team comprises medical writers and HTA writing leads, all trained in value communication, HTA writing, and HTA processes.
Integrated expertise
Writers at principal level and above each bring at least 6 years of market access and HTA writing experience, so your value story is shaped by people who understand not just how to write it, but also how it will be scrutinised.
Strategic collaboration
We work in close partnership with clients, taking a collaborative approach to every project. Senior team members lead throughout, co-creating the strategy with you while providing expert advice and guidance at each stage, not simply executing a brief handed down.
Agile delivery
Where needed, we also support stakeholder training to ensure alignment and effective delivery, helping build long-term client relationships based on trust, continuity and shared success, underpinned by adaptable ways of working that flex around your priorities as they change.
Client testimonials
“Now that we have overcome the final hurdle, I just wanted to say a big thank you for all your support with this leave piece. I am really happy with how it has turned out! Thank you for all your patience with the review process and the ever-present challenges of navigating Veeva. As I mentioned earlier, <client> has been getting requests to see it from pharmacists and is all primed to go. It will definitely be of value.”
Let’s shape your value story
Whether you need a value dossier, a country-specific reimbursement submission, or ongoing support with your value communication, talk to us about your needs.
FAQ — Market Access & Value Communication
Blank 1
What is a value dossier, and how is it different from an HTA submission dossier?
A global or core value dossier sets out the overarching evidence and value story for a treatment, designed to be adapted across markets. A country-specific HTA submission dossier takes that core story and tailors it to the specific format, evidence requirements and comparators for a particular HTA agency.
What is a value message hierarchy, and why does it matter?
A value message hierarchy structures the information supporting a treatment’s evidence-based claims, from the core value proposition down to supporting detail. It matters because it keeps all downstream materials (for example, slide decks, objection handlers, briefing books) consistent, so that payers and stakeholders hear the same prioritised story regardless of which document they’re reading.
Do you support publications like manuscripts and conference posters, not just formal submissions?
Yes, we develop conference abstracts, posters, and manuscripts, and help with identifying the optimal journal, and tailoring the writing style and content to suit the intended audience. Publishing research helps evidence reach a wider audience and can build credibility that can indirectly support an HTA submission.
Can you adapt a global value story for a country-specific submission?
Yes, we regularly adapt information within a global or core value dossier to a specific market’s HTA requirements, comparators and payer expectations.
Do you offer stakeholder training alongside value communication deliverables?
Yes, where needed we support with training to help internal teams and stakeholders use and present value communication materials effectively, ensuring alignment beyond the documents themselves.